AGOMAB IS LEVERAGING NEW SCIENTIFIC INSIGHTS AND ESTABLISHED DRUG DEVELOPMENT EXPERTISE TO HARNESS THE DISEASE MODIFYING POTENTIAL OF GROWTH FACTOR MODULATING THERAPEUTICS
Fibrotic processes are the underlying factors in a variety of difficult-to-treat diseases, resulting in progressive organ failure. Agomab aims to resolve these processes through a broad pipeline of small molecule and antibody drug candidates designed for their unique and novel modes of actions against well-validated and potentially disease modifying targets, ultimately leading to repair of tissue injury, resolution of fibrosis and restoration of organ function.
![](/wp-content/uploads/2023/12/Pipeline-for-website-1.png)
“Our pipeline will continue to grow with the addition of both novel antibody and small molecule drug candidates that we are designing with the goal of bringing a range of truly disease-modifying treatments to patients in need.”
Philippe Wiesel, Chief Medical Officer